Hyperfine reaffirms 2026 revenue outlook of approximately $20 million to $22 million
Bitget2026/10/08 11:31Hyperfine reaffirmed full-year 2026 revenue outlook of USD 20 million to USD 22 million. Full-year 2026 net cash burn forecast, excluding financing proceeds, held at about USD 26 million to USD 28 million. Third-quarter preliminary revenue seen at about USD 6 million, up 53% sequentially. Third-quarter net cash burn estimated at about USD 5.6 million, a 29% sequential improvement; cash projected at about USD 37.9 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hyperfine Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610080730BIZWIRE_USPR_____20261008_BW951075) on October 08, 2026, and is solely responsible for the information contained therein.
- Hyperfine reaffirmed full-year 2026 revenue outlook of USD 20 million to USD 22 million.
- Full-year 2026 net cash burn forecast, excluding financing proceeds, held at about USD 26 million to USD 28 million.
- Third-quarter preliminary revenue seen at about USD 6 million, up 53% sequentially.
- Third-quarter net cash burn estimated at about USD 5.6 million, a 29% sequential improvement; cash projected at about USD 37.9 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
